UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 24, 2007
Date of Report (Date of earliest event reported)
Avantogen Oncology, Inc.
(Exact name of registrant as specified in its charter)
| Nevada | 33-55254-28 | 87-0438641 |
| (State or Other Jurisdiction | (Commission File Number) | (IRS Employer |
| of Incorporation) | | Identification Number) |
2121 Avenue of the Stars, Suite 2550, Los Angeles, California 90067
(Address of Principal Executive Offices) (Zip Code)
310-277-2077
(Registrant’s telephone number, including area code)
N/A
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Section 5 - Corporate Governance and Management
Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers; Compensatory Arrangements of Certain Officers.
On January 24, 2007, William Ardrey and Michael Hillmeyer were appointed as directors of registrant. Mr. Ardrey and Mr. Hillmeyer, both of whom are also directors of Avantogen Limited, registrant’s largest shareholder, will fill the Avantogen Limited director-designee vacancies created as a result of the resignations of Richard Opara and Joseph Boystak.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | Avantogen Oncology, Inc. |
| | | |
| | | By: /s/ Christopher Nowers |
| | | Christopher Nowers |
| | | Chief Executive Officer |
| Date: January 30, 2007 | | |
